UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study

Clinical pharmacology and therapeutics, 2019-04, Vol.105 (4), p.1031-1039

2019

Volltextzugriff (PDF)

M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model

American journal of obstetrics and gynecology, 2019-05, Vol.220 (5), p.498.e1-498.e9

2019

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study

Frontiers in neuroscience, 2024-02, Vol.18, p.1302714-1302714

2024

Volltextzugriff (PDF)

Tgf-beta type I receptor (Alk5) kinase inhibitors in oncology

Current pharmaceutical biotechnology, 2011-12, Vol.12 (12), p.2190-2202

2011

Volltextzugriff (PDF)

Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor

Arthritis research & therapy, 2019-10, Vol.21 (1), p.216-216, Article 216

2019

Volltextzugriff (PDF)

Small Molecular Inhibitor of Transforming Growth Factor-β Protects Against Development of Radiation-Induced Lung Injury

International journal of radiation oncology, biology, physics, 2008-07, Vol.71 (3), p.829-837

2008

Volltextzugriff (PDF)

The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors

Nature medicine, 2001-06, Vol.7 (6), p.706-711

2001

Volltextzugriff (PDF)

Transforming Growth Factor-β Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers

Clinical cancer research, 2008-06, Vol.14 (12), p.3966-3974

2008

Volltextzugriff (PDF)

Postnatal recapitulation of embryonic hedgehog pathway in response to skeletal muscle ischemia

Circulation (New York, N.Y.), 2003-07, Vol.108 (4), p.479-485

2003

Volltextzugriff (PDF)

Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn

The New England journal of medicine, 2024-08, Vol.391 (6), p.526-537

2024

Volltextzugriff (PDF)

Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010

AJOG global reports, 2023-05, Vol.3 (2), p.100203-100203, Article 100203

2023

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers

Clinical drug investigation, 2024-08, Vol.44 (8), p.587-599

2024

Volltextzugriff (PDF)

Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn

American journal of perinatology, 2024-09

2024

Volltextzugriff (PDF)

Soluble Type II Transforming Growth Factor-β Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity

Clinical cancer research, 2004-09, Vol.10 (17), p.5907-5918

2004

Volltextzugriff (PDF)

The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis

Cancer Immunology, Immunotherapy, 2012-04, Vol.61 (4), p.511-521

2012

Volltextzugriff (PDF)

Sonic Hedgehog Restricts Adhesion and Migration of Neural Crest Cells Independently of the Patched-Smoothened-Gli Signaling Pathway

Proceedings of the National Academy of Sciences - PNAS, 2001-10, Vol.98 (22), p.12521-12526

2001

Volltextzugriff (PDF)

A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection

Cancer research (Chicago, Ill.), 2007-03, Vol.67 (5), p.2351-2359

2007

Volltextzugriff (PDF)

Intracellular TGF-β Receptor Blockade Abrogates Smad-Dependent Fibroblast Activation In Vitro and In Vivo

Journal of investigative dermatology, 2006-08, Vol.126 (8), p.1733-1744

2006

Volltextzugriff (PDF)

Circulating Markers of Inflammation Persist in Children and Adults With Giant Aneurysms After Kawasaki Disease

Circulation. Genomic and precision medicine, 2019-04, Vol.12 (4), p.e002433-e002433

2019

Volltextzugriff (PDF)

STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade

Cancer immunology research, 2015-05, Vol.3 (5), p.526-535

2015

Volltextzugriff (PDF)

SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model

Arteriosclerosis, thrombosis, and vascular biology, 2008-04, Vol.28 (4), p.665-671

2008

Volltextzugriff (PDF)

A Quantitative Microtiter Assay for Sialylated Glycoform Analyses Using Lectin Complexes

Journal of biomolecular screening, 2015-07, Vol.20 (6), p.768-778

2015

Volltextzugriff (PDF)

Successful shape-based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)

Bioorganic & medicinal chemistry letters, 2003-12, Vol.13 (24), p.4355-4359

2003

Volltextzugriff (PDF)

An Orally Active Small Molecule TGF-β Receptor I Antagonist Inhibits the Growth of Metastatic Murine Breast Cancer

Anticancer research, 2009-06, Vol.29 (6), p.2099-2109

2009

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered at Different Rates of Intravenous Infusion in Healthy Participants: Results of a Phase 1 Placebo-Controlled Single-Dose Study

Blood, 2022-11, Vol.140 (Supplement 1), p.11039-11040

2022

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(56)
Buchkapitel
(1)

Sprache

Englisch
(57)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(32)
Animals
(18)
Humans
(18)
Female
(14)
Biological And Medical Sciences
(10)
Mice
(10)
Oncology
(9)
Biochemistry & Molecular Biology
(8)
Medical Sciences
(8)
Receptors, Transforming Growth Factor Beta - Antagonists & Inhibitors
(8)
Tumors
(7)
Male
(6)
Azabicyclo Compounds - Administration & Dosage
(5)
Cell Biology
(5)
Mice, Inbred Balb C
(5)
Pharmacology. Drug Treatments
(5)
Adult
(4)
Antineoplastic Agents
(4)
Cells, Cultured
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study

M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model

Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study

Tgf-beta type I receptor (Alk5) kinase inhibitors in oncology

Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor

Small Molecular Inhibitor of Transforming Growth Factor-β Protects Against Development of Radiation-Induced Lung Injury

The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors

Transforming Growth Factor-β Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers

Postnatal recapitulation of embryonic hedgehog pathway in response to skeletal muscle ischemia

Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn

Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010

Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers

Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn

Soluble Type II Transforming Growth Factor-β Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity

The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis

Sonic Hedgehog Restricts Adhesion and Migration of Neural Crest Cells Independently of the Patched-Smoothened-Gli Signaling Pathway

A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection

Intracellular TGF-β Receptor Blockade Abrogates Smad-Dependent Fibroblast Activation In Vitro and In Vivo

Circulating Markers of Inflammation Persist in Children and Adults With Giant Aneurysms After Kawasaki Disease

STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade

SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model

A Quantitative Microtiter Assay for Sialylated Glycoform Analyses Using Lectin Complexes

Successful shape-based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)

An Orally Active Small Molecule TGF-β Receptor I Antagonist Inhibits the Growth of Metastatic Murine Breast Cancer

Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered at Different Rates of Intravenous Infusion in Healthy Participants: Results of a Phase 1 Placebo-Controlled Single-Dose Study

Suchergebnisse filtern